MSI2 and nonpapillary renal cell carcinoma: It was found that in ccRCC patients with high Musashi-2 expression, sorafenib, sunitinib, temsirolimus and gefitinib had lower IC50 values (Figures 7A, B, E, F), reflecting higher sensitivity to targeted drug treatment.